Given the strong evidence of a pathogenic role of BTK in autoimmunity, several small-molecule BTKi with higher selectivity and low potential for off-target related adverse effects are being explored as a therapeutic option and are in the early phase of development for treatment of autoimmune diseases including MS, RA, pemphigus, and SLE [68,70,81]. This evidence concerns the gene BTK and Autoimmunity.